Research programme: antithrombotic peptides - Bioxodes

Drug Profile

Research programme: antithrombotic peptides - Bioxodes

Alternative Names: Ir-CPI

Latest Information Update: 16 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Free University of Brussels
  • Developer Bioxodes
  • Class Peptides
  • Mechanism of Action Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 08 Jan 2014 Preclinical trials in Thrombosis (prevention) in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top